Loading
Crowdcube's Cell Therapy offers to buy out shareholders with a return but loss of EIS reliefs
Cell therapy raised over £600k in December 2014. Now new investment from Japan has enabled a company restructuring and an offer to shareholders to either take a share swop or cash - representing an almost 2X gain.
This is Crowdcube's best result to date. Shareholders paid £37 in 2014 and 24 moths later they are being offered £101.
Although it is not all good news.
EIS reliefs which would have been taken by all B shareholders for tax year 2103/14, will have to be recharged if they opt to sell - with interest. They will also be liable to the...
This is a premium article.
You need to be an ECF.BUZZ member to read the full thing. Join now for only £3 per month!
Friday March 10, 2017
Hardman and Co’s Brian Moretta in conversation with ECF Buzz Founder Rob Murray Brown on start up investing, equity crowdfunding and what’s a good read.